Study of Safety, PK, and Efficacy of Multiple Ascending Doses of HZBio1 in Patients With Gout

NCT07752810 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Gout

Interventions

DRUG: Phase 1b: HZBio1 3mg
DRUG: Phase 1b: HZBio1 6mg
DRUG: Phase 1b: HZBio1 12mg
DRUG: Phase 2: HZBio1 6mg
DRUG: Phase 2: HZBio1 9mg
DRUG: Phase 2: HZBio1 12mg

Sponsor

Hangzhou Grand Biologic Pharmaceutical, Inc.